Oral chemotherapy in the treatment of hormone-refractory prostate cancer

Kenneth J. Pienta, Jeffrey M. Kamradt, David C. Smith

Research output: Contribution to journalArticle

Abstract

Oral chemotherapy has become a major component of the treatment of advanced prostate cancer. The recognition that prostate cancer grows very slowly and must be treated continuously with active agents has led to the development of several therapeutic regimens. These regimens employ oral agents such as estramustine, cyclophosphamide, and etoposide, as they can be taken on a daily basis at home by the patients. These regimens have demonstrated activity in patients with hormone-refractory prostate cancer; declines in both prostate specific antigen and soft tissue lesions have been demonstrated.

Original languageEnglish (US)
Pages (from-to)127-131
Number of pages5
JournalDrugs
Volume58
Issue numberSUPPL. 3
StatePublished - Dec 1 1999
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Oral chemotherapy in the treatment of hormone-refractory prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Pienta, K. J., Kamradt, J. M., & Smith, D. C. (1999). Oral chemotherapy in the treatment of hormone-refractory prostate cancer. Drugs, 58(SUPPL. 3), 127-131.